CPT code 0206U is a Proprietary Laboratory Analyses (PLA) code that identifies the Discern™ test by NeuroDiagnostics, a laboratory assay that uses morphometric imaging and protein kinase C–epsilon (PKCε) biomarker measurement on cultured skin specimens to assist in identifying Alzheimer disease. As a PLA code, 0206U is tied to a single manufacturer's proprietary test, which has implications for coding specificity, payer coverage determinations, and lab billing workflows nationally. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn what CPT code 0206U represents clinically and operationally, how it typically fits into diagnostic pathways for suspected Alzheimer disease, and which major payers are relevant for coverage considerations. The publication outlines common payer interactions, typical site-of-service patterns for specimen collection and laboratory testing, and the policy and billing context that affects adoption of PLA-coded assays. It also summarizes available benchmarks and areas where policy updates or payer guidance may affect claims processing and lab reimbursement. Data not available in the input is noted where applicable.